Verona Pharma plc (I9SA) - Total Liabilities
Based on the latest financial reports, Verona Pharma plc (I9SA) has total liabilities worth €294.60 Million EUR (≈ $344.42 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore I9SA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Verona Pharma plc - Total Liabilities Trend (2016–2024)
This chart illustrates how Verona Pharma plc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Verona Pharma plc (I9SA) total assets.
Verona Pharma plc Competitors by Total Liabilities
The table below lists competitors of Verona Pharma plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CareTrust REIT Inc.
NYSE:CTRE
|
USA | $1.08 Billion |
|
AVIC Aircraft Co Ltd
SHE:000768
|
China | CN¥54.73 Billion |
|
Vibra Energia S.A.
SA:VBBR3
|
Brazil | R$39.65 Billion |
|
China XD Electric Co Ltd
SHG:601179
|
China | CN¥21.69 Billion |
|
CubeSmart
NYSE:CUBE
|
USA | $3.86 Billion |
|
FREEDOM HLDG DL-001
F:DMW2
|
Germany | €12.51 Billion |
|
KT Corporation
NYSE:KT
|
USA | $23.17 Trillion |
|
Ingenic Semiconductor
SHE:300223
|
China | CN¥1.38 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Verona Pharma plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Verona Pharma plc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Verona Pharma plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Verona Pharma plc (2016–2024)
The table below shows the annual total liabilities of Verona Pharma plc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €269.68 Million ≈ $315.29 Million |
+358.32% |
| 2023-12-31 | €58.84 Million ≈ $68.79 Million |
+102.89% |
| 2022-12-31 | €29.00 Million ≈ $33.91 Million |
-24.83% |
| 2021-12-31 | €38.58 Million ≈ $45.11 Million |
+99.37% |
| 2020-12-31 | €19.35 Million ≈ $22.62 Million |
+30.96% |
| 2019-12-31 | €14.78 Million ≈ $17.28 Million |
+2.81% |
| 2018-12-31 | €14.37 Million ≈ $16.80 Million |
+10.52% |
| 2017-12-31 | €13.00 Million ≈ $15.20 Million |
-9.71% |
| 2016-12-31 | €14.40 Million ≈ $16.84 Million |
-- |
About Verona Pharma plc
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more